These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33986457)

  • 21. Cross-sectional associations between exposure to per- and polyfluoroalkyl substances and body mass index among European teenagers in the HBM4EU aligned studies.
    Schillemans T; Iszatt N; Remy S; Schoeters G; Fernández MF; D'Cruz SC; Desalegn A; Haug LS; Lignell S; Lindroos AK; Fábelová L; Murinova LP; Kosjek T; Tkalec Ž; Gabriel C; Sarigiannis D; Pedraza-Díaz S; Esteban-López M; Castaño A; Rambaud L; Riou M; Pauwels S; Vanlarebeke N; Kolossa-Gehring M; Vogel N; Uhl M; Govarts E; Åkesson A
    Environ Pollut; 2023 Jan; 316(Pt 1):120566. PubMed ID: 36334774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic review and meta-analysis of epidemiologic data on vaccine response in relation to exposure to five principal perfluoroalkyl substances.
    Crawford L; Halperin SA; Dzierlenga MW; Skidmore B; Linakis MW; Nakagawa S; Longnecker MP
    Environ Int; 2023 Feb; 172():107734. PubMed ID: 36764183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances.
    Porter AK; Kleinschmidt SE; Andres KL; Reusch CN; Krisko RM; Taiwo OA; Olsen GW; Longnecker MP
    Environ Int; 2022 Nov; 169():107537. PubMed ID: 36183490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perfluoroalkyl substances and sex hormones in postmenopausal women: NHANES 2013-2016.
    Wang Y; Aimuzi R; Nian M; Zhang Y; Luo K; Zhang J
    Environ Int; 2021 Apr; 149():106408. PubMed ID: 33548847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concentrations of perfluoroalkyl and polyfluoroalkyl substances and blood glucose in pregnant women.
    Ren Y; Jin L; Yang F; Liang H; Zhang Z; Du J; Song X; Miao M; Yuan W
    Environ Health; 2020 Aug; 19(1):88. PubMed ID: 32807188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perfluoroalkyl substances and changes in body weight and resting metabolic rate in response to weight-loss diets: A prospective study.
    Liu G; Dhana K; Furtado JD; Rood J; Zong G; Liang L; Qi L; Bray GA; DeJonge L; Coull B; Grandjean P; Sun Q
    PLoS Med; 2018 Feb; 15(2):e1002502. PubMed ID: 29438414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Perfluoroalkyl and Polyfluoroalkyl Substances With Premature Ovarian Insufficiency in Chinese Women.
    Zhang S; Tan R; Pan R; Xiong J; Tian Y; Wu J; Chen L
    J Clin Endocrinol Metab; 2018 Jul; 103(7):2543-2551. PubMed ID: 29986037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temporal trends of concentrations of per- and polyfluoroalkyl substances among adults with overweight and obesity in the United States: Results from the Diabetes Prevention Program and NHANES.
    Lin PD; Cardenas A; Hauser R; Gold DR; Kleinman KP; Hivert MF; Calafat AM; Webster TF; Horton ES; Oken E
    Environ Int; 2021 Dec; 157():106789. PubMed ID: 34333293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physical activity is associated with risk factors for chronic disease across adult women's life cycle.
    Woolf K; Reese CE; Mason MP; Beaird LC; Tudor-Locke C; Vaughan LA
    J Am Diet Assoc; 2008 Jun; 108(6):948-59. PubMed ID: 18502225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Per- and polyfluoroalkyl substances and kidney function: Follow-up results from the Diabetes Prevention Program trial.
    Lin PD; Cardenas A; Hauser R; Gold DR; Kleinman KP; Hivert MF; Calafat AM; Webster TF; Horton ES; Oken E
    Environ Int; 2021 Mar; 148():106375. PubMed ID: 33482440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Pregnancy Plasma Per- and Polyfluoroalkyl Substances (PFAS) and Maternal Midlife Adiposity.
    Burdeau JA; Stephenson BJK; Chavarro JE; Mahalingaiah S; Preston EV; Hivert MF; Oken E; Calafat AM; Rifas-Shiman SL; Zota AR; James-Todd T
    J Clin Endocrinol Metab; 2024 Sep; ():. PubMed ID: 39235224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between Perfluoroalkyl and Polyfluoroalkyl Substances and Women's Infertility, NHANES 2013-2016.
    Tan Y; Zeng Z; Liang H; Weng X; Yao H; Fu Y; Li Y; Chen J; Wei X; Jing C
    Int J Environ Res Public Health; 2022 Nov; 19(22):. PubMed ID: 36430067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prenatal exposure to perfluoroalkyl substances and birth outcomes in a Spanish birth cohort.
    Manzano-Salgado CB; Casas M; Lopez-Espinosa MJ; Ballester F; Iñiguez C; Martinez D; Costa O; Santa-Marina L; Pereda-Pereda E; Schettgen T; Sunyer J; Vrijheid M
    Environ Int; 2017 Nov; 108():278-284. PubMed ID: 28917208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perfluoroalkyl Substances during Pregnancy and Offspring Weight and Adiposity at Birth: Examining Mediation by Maternal Fasting Glucose in the Healthy Start Study.
    Starling AP; Adgate JL; Hamman RF; Kechris K; Calafat AM; Ye X; Dabelea D
    Environ Health Perspect; 2017 Jun; 125(6):067016. PubMed ID: 28669937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dietary characteristics associated with plasma concentrations of per- and polyfluoroalkyl substances among adults with pre-diabetes: Cross-sectional results from the Diabetes Prevention Program Trial.
    Lin PD; Cardenas A; Hauser R; Gold DR; Kleinman KP; Hivert MF; Fleisch AF; Calafat AM; Sanchez-Guerra M; Osorio-Yáñez C; Webster TF; Horton ES; Oken E
    Environ Int; 2020 Apr; 137():105217. PubMed ID: 32086073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prenatal exposure to per- and polyfluoroalkyl substances and maternal and neonatal thyroid function in the Project Viva Cohort: A mixtures approach.
    Preston EV; Webster TF; Claus Henn B; McClean MD; Gennings C; Oken E; Rifas-Shiman SL; Pearce EN; Calafat AM; Fleisch AF; Sagiv SK
    Environ Int; 2020 Jun; 139():105728. PubMed ID: 32311629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Individual and mixture associations of perfluoroalkyl substances on liver function biomarkers in the Canadian Health Measures Survey.
    Borghese MM; Liang CL; Owen J; Fisher M
    Environ Health; 2022 Sep; 21(1):85. PubMed ID: 36104725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perfluoroalkyl substances and changes in bone mineral density: A prospective analysis in the POUNDS-LOST study.
    Hu Y; Liu G; Rood J; Liang L; Bray GA; de Jonge L; Coull B; Furtado JD; Qi L; Grandjean P; Sun Q
    Environ Res; 2019 Dec; 179(Pt A):108775. PubMed ID: 31593837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations between exposure to a mixture of perfluoroalkyl and polyfluoroalkyl substances and age at menarche in adolescent girls utilizing three statistical models.
    Guo M; Yu Y; Liu H; Zhu C
    Chemosphere; 2023 Sep; 335():139054. PubMed ID: 37247673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone mass density following developmental exposures to perfluoroalkyl substances (PFAS): a longitudinal cohort study.
    Blomberg A; Mortensen J; Weihe P; Grandjean P
    Environ Health; 2022 Nov; 21(1):113. PubMed ID: 36402982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.